Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

In this analysis presented at the American Academy of Dermatology annual meeting, serious adverse events were low, unrelated ...

It can be hard to tell for sure if you have atopic dermatitis, also known as eczema ... and topical ruxolitinib (Opzelura). They are used for moderate to severe AD in those over 12.

Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...

Discover a study that aimed to compare the effects of antimicrobial–corticosteroid combination therapy with corticosteroid ...

with Opzelura's approval for pediatric Atopic Dermatitis (AD) seen as a modest growth driver. Notably, Incyte maintains a strong financial position with more cash than debt on its balance sheet ...

The 2021-approved Opzelura grew sales by 50% during 2024, reaching $508 million on the back of its two approved indications in atopic dermatitis and vitiligo. Included in the fourth quarter’s $ ...

In dermatology, we see strong potential for a topical version of the active ingredient in Jakafi (ruxolitinib), which was approved in 2021 in atopic dermatitis as Opzelura and received a label ...

Clinical phenotypes of atopic dermatitis can vary greatly based on skin color and can make atopic dermatitis difficult to diagnose.